25th Apr 2019 12:32
LONDON (Alliance News) - Silence Therapeutics PLC said Thursday it had reappointed Iain Ross as chair of the genetic medicines firm with immediate effect, alongside the hiring of another non-executive.
Ross - who previously served as chair between 2005 and 2010 - has been reappointed as non-executive and chair of Silence. He is currenty non-executive at e-Therapeutics PLC and Redx Pharma PLC.
Previously, he has held a number of senior commercial roles at Sandoz, Fisons and Hoffman La Roche before taking on a series of chair and chief executive roles in the biotechnology sector.
Ross explained he was "delighted to be returning to Silence Therapeutics".
"With a renewed strategy in place and a return to the clinic imminent I believe Silence now represents a fundamentally transformed value proposition and I am excited to work with the team and to bring some stability to the board to deliver on its potential", Ross added.
In addition to Ross, Silence was replacing Non-Executive Director Stephen Parker with James Ede-Golightly after Parker decided to stand down from the firm.
Ede-Golightly served as an analyst for Merrill Lynch and Commerzbank before founding ORA Capital Partners in 2006. He is currently chair of DeepMatter Group PLC.
"I'm very pleased to welcome Iain Ross and James Ede-Golightly to the board of directors," Silence Chief Executive Officer David Horn Solomon said. "Iain brings with him extensive healthcare and governance experience and I am looking forward to working with him to build significant value for shareholders, patients and their caregivers. I would also like to thank Stephen for his service as a valued Board member and advisor."
Shares in Silence were 4.3% higher at 73.00 pence on Thursday.
Related Shares:
SLN.L